Michel Bosch

November is #LungCancerAwarenessMonth. A time to shed a light on this disease - spreading essential knowledge for early detection.   In Switzerland around 4,800 people are diagnosed with lung cancer every year, with around 3,300 of those resulting in death. Most types of lung cancer do not cause symptoms until they have advanced, leading to late-stage diagnoses. While active and passive smoking are well-known risk factors and account for 80% of lung cancer deaths in the EU – other factors like radon gas, air pollution, and genetic mutations also contribute to the disease.   Therefore, raising awareness, getting regular check-ups, and understanding all potential risk factors are crucial steps in combating lung cancer. At Bristol Myers Squibb, we’re driven by a profound commitment to transforming the future of cancer care by creating innovative treatment and therapy options for those affected. Not only during Lung Cancer Awareness Month, but every day.   #BMSwitzerland #LungCancerAwareness #LungHealth   Source: Cancer Screening Committee (2024), Lung Cancer Screening using LDCT

52

#ICYMI Our CEO Sarah Howell, and Thomas Pieber from the Medical University of Graz, Austria, and Principal Investigator for the AT278 Phase I clinical trial in Type 2 diabetics with a high BMI, hosted a webinar last week to discuss the recent positive headline clinical results for AT278, our ultra-concentrated, ultra-rapid acting insulin candidate. Sarah and Thomas highlighted the significance of our latest clinical results, with AT278 demonstrating a fast and superior onset of action and glucose lowering profile, and explored the potential of the only concentrated, yet very rapid acting, insulin in development, to enable the next generation of miniaturised, longer-wear insulin pumps – ultimately reducing the burden for patients and transforming future diabetes management. To watch the full recording, click here: https://lnkd.in/eczwHZet #Arecor #insulinPumps #diabetes #biotech #drugDevelopment #webinar #KOL

25

1 Kommentar

𝐓𝐨𝐝𝐚𝐲 𝐢𝐬 "𝐖𝐨𝐫𝐥𝐝 𝐈𝐁𝐃 𝐃𝐚𝐲" 📅 𝐓𝐡𝐞𝐫𝐞 𝐢𝐬 𝐧𝐨 𝐜𝐮𝐫𝐞 𝐟𝐨𝐫 𝐢𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐨𝐫𝐲 𝐛𝐨𝐰𝐞𝐥 𝐝𝐢𝐬𝐞𝐚𝐬𝐞. 𝐓𝐡𝐞 𝐜𝐚𝐮𝐬𝐞𝐬 𝐚𝐫𝐞 𝐮𝐧𝐤𝐧𝐨𝐰𝐧 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐥𝐞𝐯𝐞𝐥 𝐨𝐟 𝐬𝐮𝐟𝐟𝐞𝐫𝐢𝐧𝐠 𝐢𝐬 𝐨𝐟𝐭𝐞𝐧 𝐡𝐢𝐠𝐡 𝐟𝐨𝐫 𝐚𝐟𝐟𝐞𝐜𝐭𝐞𝐝 𝐩𝐞𝐨𝐩𝐥𝐞 𝐨𝐟 𝐚𝐥𝐥 𝐚𝐠𝐞𝐬. This is why it is so important not only to raise awareness of these indications, but also to optimize processes in the healthcare system in order to bring treatment alternatives to patients as quickly as possible. Our path goes through the #pharma companies that want to reach the relevant #HCPs. For Crohn's disease and ulcerative colitis, we have carried out a rough #targeting exclusively on these two terms, which on the one hand takes into account the global research situation and on the other hand also examines the treatment situation specifically in Germany. This is obviously not sufficient for our pharmaceutical projects. A content frame would completely refine the targeting and the figures below can therefore change dynamically in both directions depending on the specificity. The #AI of Vertical Search Health identifies the papers relevant to these two indications worldwide in order to filter out research-relevant HCPs around the world that have recently devoted themselves to this topic or which HCPs have collaborated on it. This would be a possible segmentation approach. For individual countries, a further segmentation approach is added that relates to the relevant practices. Using Germany as an example, we have analyzed the entire outpatient healthcare market so that 2 segmentations are possible, as in the example below. Other options, such as web search or the patient perspective, can also be added. The pharmaceutical industry is working tirelessly on new drug innovations in the indication of #IBD - we are pleased to be part of it with our data to identify exactly the most relevant doctors who then bring the innovations to the patients. Marcus Bergler Karsten Schmidt Gaby Perfahl Wolfgang Höfers Torsten B. Christann AbbVie Bristol Myers Squibb Immundiagnostik AG Takeda in Deutschland Dr. Falk Pharma Alfasigma Biogen Fresenius Kabi Amgen Nestlé Health Science

9

1 Kommentar

+++ 𝗤𝟭 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝟮𝟬𝟮𝟰 𝗮𝗻𝗱 𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝘂𝗽𝗱𝗮𝘁𝗲 +++ We started the year with good progress across our oncology pipeline and our commercialization activities. Some key events: 🔬 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆: We and our collaboration partner Duality Biologics dosed the first patient in a Phase 3 clinical trial with our #ADC candidate BNT323/DB-1303 in breast cancer patients, advancing towards BioNTech’s goal of ten or more potentially registrational trials running by the end of 2024. 🩹 𝗖𝗢𝗩𝗜𝗗-𝟭𝟵: We are focusing on preparing for variant-strain adaptation of our COVID-19 vaccine to be ready for a commercial launch ahead of the upcoming 2024/2025 vaccination season, pending approvals. 🌎 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗿𝗲𝗮𝗱𝗶𝗻𝗲𝘀𝘀: We appointed our General Manager Fatma Ocak for the U.S. in line with our commercial preparations to drive our first expected global #oncology product launch. 𝗟𝗶𝗻𝗸 𝘁𝗼 𝗣𝗥 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: https://lnkd.in/ePDQiHbH  

550

2 Kommentare

HCP perspectives: Access challenges in treating diabetes and obesity. Highlights of a candid discussion between specialists about the issues HCPs face in the diagnosis and treatment of diabetes and obesity. GoodRx https://brnw.ch/21wKcXy #partnercontent #HCPs #diabetes #obesity

2

📌Gunnar Schroefel about the impact of the #europeancancersummit , the most pressing issue in oncology and his opinion of #OncoDaily European Cancer Organisation Daiichi Sankyo Europe GmbH #Cancer #GlobalOncology #Healthcare #MedNews #Health #Medicine #OncoDaily #Oncology

14

🚀 New Hope for Lung Cancer Patients! 🌟 The German healthcare authority has officially launched the benefit assessment for Tislelizumab (Tevimbra), targeting advanced non-small cell lung carcinoma (NSCLC) with specific genetic markers. This promising therapy, developed by BeiGene Germany GmbH, is set to enhance treatment options for patients exhibiting PD-L1 expression of 50% or higher. 🗓️ Key Dates: - Assessment began: January 1, 2025 - Public results release: April 1, 2025 - Stakeholder comments due by: April 22, 2025 - Final decision expected: Mid-June 2025 This initiative reflects Germany's commitment to advancing cancer treatments through rigorous evaluation processes. The combination of Tislelizumab with pemetrexed and platinum chemotherapy could significantly improve patient outcomes. Stay tuned as we monitor this critical development in oncology! #HealthTechnologyAssessment #HealthcareInnovation #LungCancer #Oncology #PatientCare #RegulatoryAgencies #Tislelizumab #MarketAccess #MarketAccessToday

1

Have you discovered Heart ❤️ to ❤️ Heart conversations yet? Hosted by Dejan Milasinovic, this PCR series features live, unscripted discussions with top experts on today’s hottest topics. Discover the concept and catch up on the first three episodes (covering #STEMI, #TAVI in low-risk patients, and left main PCI with intracoronary #imaging) to get a taste of what's coming next! ➡ https://lnkd.in/dMBBNbCq #cardioed #interventionalcardiology

42

At the recent German Network for Personalised Medicine (DNPM) congress, Josef Hecken, chairman of the Federal Joint Committee (G-BA), shared key shared innovative approaches to evidence generation and patient care, signalling a shift from traditional drug trials. This could mean easier access to personalised therapies, benefiting both patients and manufacturers. 🏥 Dive into the details and implications of this transformative change in our latest insider insight ➡ 🔗 https://lnkd.in/evj6naTn #MarketAccess #PatientAccess #PersonalisedMedicine #HealthcareInnovation #DrugTrials #Pharma #Biotech #PatientCare * 𝒘𝒓𝒊𝒕𝒕𝒆𝒏 𝒃𝒚 Manahill Baig

3

This #WorldDiabetesDay, our President, Prof. Dr. med. habil. Peter Egbert Hermann Schwarz, highlights the need to prioritise the well-being and quality of life for people living with diabetes. With 70% facing quality-of-life challenges and 80% experiencing burnout, we must take steps, big or small, to support them. Join us in making a positive impact for all people affected by diabetes. #diabeteslife

37

Swissmedic's 2023 report on human medicines: a leap forward in healthcare innovation Swissmedic's 2023 report reveals a significant year for healthcare innovation: 41 new active substances and 65 additional indications were approved, enhancing treatment options across various diseases. The median review time was reduced to 441 days, highlighting efficiency in regulatory processes. Key areas include oncology, infectious diseases and neurology. The international approval projects #AccessConsortium and #ProjectOrbis are increasingly being used for accelerated approval alternatives. This year's progress underscores Switzerland's commitment to advancing public health through timely access to innovative treatments. Dive into our extended analysis on Swissmedic’s 2023 approvals by visiting our blog: https://lnkd.in/dzSuCRD8 #SwizzardPharma #HealthcareInnovation #Swissmedic2023 #Pharmaceuticals Michael Zürcher, PhD EMBA Bettina Schelbert Karin Senn Mathieu Bitz Yves Heller Joël Heller Luc Heller Julia Mühlethaler Arne Holicki

14

4SC is headed to the #EORTC Cutaneous Lymphoma Tumour Group (CLTG) Annual Meeting from 9-11 October.   Reach out to us if you would like to meet our Chief Medical Officer Susanne Danhauser-Riedl or Head of Project Management Matthias Borgmann to learn about the #RESMAIN study which investigated the efficacy of #resminostat (#Kinselby) as a maintenance treatment for cutaneous T-cell lymphoma (#CTLC).   #EORTCCLTG #RESMAINstudy #RareDisease #BloodCancer

31

The Rare Disease Action Forum brings together voices from actors in the field of rare diseases representing the industry, healthcare professionals, patient and research organizations to improve the lives of patients with rare diseases in Switzerland. Our objectives include: 👉 Raising awareness about rare diseases in Switzerland and foster dialogue about patients’ needs 👉 Assessing and adapting the Swiss environment to the needs of patients with rare diseases 👉 Adapting the standards to enable equal and fair treatment for patients with rare diseases Join our multi-stakeholder association or discover more RDAF objectives: https://bit.ly/3nKB4B1 #rarediseases #Switzerland

4

❓ If my patient has a kidney disease, why should I inform her / him about heart disease? ❓ How are kidney disease and heart disease related? ❓ How do I treat kidney disease and heart disease? ❓ What are the current outcomes of clinical trials, and study results? 💡 Our expert 🗣 Danilo Fliser will update you on 💔 Cardiovascular Disease at the 8th Nephro Update Europe. Face-to-face in #Vienna or via #livestream on the 6 - 7 September, 2024 you will be provided with unbiased interpretation of 📅 the most recent study results, 📝 no repetition of existing state-of-the-art knowledge. You can register here: https://lnkd.in/evrQk_UA We are looking forward to having you! #nephrology #nefrologia #kidneydiseas #heartdiseas #cardiovasculardisease #cardiology #cardiologia #herzundniere

1

🔔 Do you want to stay up-to-date on the latest developments in therapeutic products? Subscribe now to our Swissmedic newsletters! 📰 Choose your preferred news subscriptions from various subject areas. Simply register and never miss out on important info! 💌 https://bit.ly/4dKaVYt #Swissmedic #Newsletter #Healthcare

10

🔔 Do you want to stay up-to-date on the latest developments in therapeutic products? Subscribe now to our Swissmedic newsletters! 📰 Choose your preferred news subscriptions from various subject areas. Simply register and never miss out on important info! 💌 https://bit.ly/4dKaVYt #Swissmedic #Newsletter #Healthcare

7

🔔 Do you want to stay up-to-date on the latest developments in therapeutic products? Subscribe now to our Swissmedic newsletters! 📰 Choose your preferred news subscriptions from various subject areas. Simply register and never miss out on important info! 💌 https://bit.ly/4dKaVYt #Swissmedic #Newsletter #Healthcare

8

1 Kommentar

🔔 Do you want to stay up-to-date on the latest developments in therapeutic products? Subscribe now to our Swissmedic newsletters! 📰 Choose your preferred news subscriptions from various subject areas. Simply register and never miss out on important info! https://bit.ly/4dKaVYt #Swissmedic #Newsletter #Healthcare

2

Transforming Swiss medicine: b-rayZ at the SP Health Colloquium in Bern🇨🇭 We are pleased to announce that b-rayZ's CEO, Cristina Rossi, will participate as a featured speaker at this year's SP Health Colloquium, scheduled for May 3rd at the Bundeshaus in Bern. This event is pivotal in discussing the integration of artificial intelligence within healthcare, with a focus on the legal, ethical, and practical dimensions. Cristina's presentation, titled "Breast Cancer Early Detection Through AI," will explore how digitalization is transforming Swiss medicine, demonstrating b-rayZ's leadership in applying AI for improved diagnostics. Her insights will underscore the growing necessity for digital tools in enhancing patient outcomes and streamlining medical processes in Switzerland. Discussions will revolve around the importance of creating transparent, safe, and well-regulated frameworks to foster the large-scale adoption of these technologies. Such frameworks are crucial for ensuring that advancements in AI are both effective and ethically implemented. b-rayZ is committed to leading by example, showing how thoughtful regulation and cutting-edge technology can coexist to revolutionize healthcare. We look forward to engaging with policymakers and industry leaders to further this cause. 🙌 #bern #ai #medicine #healthcare #swiss #artificialintelligence #medtech

24